The Journal of Rheumatology · 2011 · 39 citations · 29 references
Life SciencesImmunologyPharmacologyInflammationRheumatologySignal TransductionAutoimmune Rheumatic DiseasesCytokine BiologyInflammatory Cell ResponsesInflammatory SignalingRheumatoid ArthritisSynovial InflammationAcute-phase ProteinsInterleukin-6 InhibitionJak-stat Pathway AntagonismJak-stat Signaling PathwayJanus Kinase Inhibitor TherapyJanus Kinase-stat Signaling ActivationRheumatoid Arthritis TherapySerum Amyloid A Protein
OBJECTIVE: Inhibition of intracellular signal transduction is considered to be a therapeutic target for chronic inflammation. The new Janus kinase (JAK)3 inhibitor CP690,550 has shown efficacy in the treatment of rheumatoid arthritis (RA). We investigated the influence of JAK/STAT inhibition using CP690,550 on the induction of acute-phase serum amyloid A (SAA), which is triggered by interleukin 6 (IL-6) stimulation in rheumatoid fibroblast-like synoviocytes (RA-FLS). METHODS: IL-6-stimulated gene expression of the acute-phase serum amyloid A genes (A-SAA; encoded by SAA1+SAA2) and SAA4 was analyzed by reverse transcriptase-polymerase chain reaction. The intracellular signaling pathway mediating the effects of CP690,550 on IL-6-stimulated JAK/STAT activation was assessed by measuring the phosphorylation levels using Western blots. RESULTS: IL-6 trans-signaling induced A-SAA messenger RNA (mRNA) expression in RA-FLS. By contrast IL-6 stimulation did not affect SAA4 mRNA expression, which is expressed constitutively in RA-FLS. IL-6 stimulation elicited rapid phosphorylation of JAK2 and STAT3, which was blunted by CP690,550. CP690,550 abrogated IL-6-mediated A-SAA mRNA expression in RA-FLS. Similarly, CP690,550 inhibited IL-6-mediated A-SAA mRNA expression in human hepatocytes. CONCLUSION: Our data indicated that CP690,550 blocked IL-6-induced JAK2/STAT3 activation, as well as the induction of A-SAA. Inhibition of IL-6-mediated proinflammatory signaling pathways by CP690,550 may represent a new antiinflammatory therapeutic strategy for RA and AA amyloidosis.
29
Natural History and Outcome in Systemic AA Amyloidosis
New England Journal of Medicine · 2007 · 878 citations · Full text
Medicine, Nephrology, Pathology +13
Natural history and outcome in systemic AA amyloidosis
UCL Discovery (University College London) · 2007 · 781 citations
Medicine, Nephrology, Pathology +13
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text
Medicine, Immunology, Pharmacology +17